The artificial vital organs and medical bionics market size has grown strongly in recent years. It will grow from $46.95 billion in 2025 to $51.07 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to limited availability of artificial organ technologies, high cost of early bionic devices, reliance on mechanical organ systems, increasing prevalence of organ failure, initial regulatory approvals for medical bionic devices.
The artificial vital organs and medical bionics market size is expected to see strong growth in the next few years. It will grow to $70.67 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to advancements in electronic and smart bionic devices, rising investment in r&d for artificial organs, increasing adoption of minimally invasive implantation procedures, growth in personalized medicine and patient-specific solutions, expansion of hospitals and clinics offering bionic therapies. Major trends in the forecast period include rising adoption of artificial heart and kidney devices, increasing integration of neural implants and bionic organs, growth in rehabilitation and assistive technologies, emphasis on customizable and patient-specific solutions, expansion of clinical trials and research applications.
The rising prevalence of organ failures is expected to propel the growth of the artificial vital organs and medical bionics market going forward. Organ failure is a serious condition in which one or more organs lose their ability to perform essential functions, resulting in severe health complications and potentially life-threatening outcomes. The increase in organ failures is driven by higher rates of chronic conditions such as diabetes, hypertension, and heart disease, as well as inherited conditions and genetic predispositions that contribute to organ failure. Artificial vital organs and medical bionics help manage organ failure by providing life-sustaining support and restoring critical functions in patients with damaged organs. For instance, in January 2025, according to the Organ Procurement and Transplantation Network, a US-based non-profit scientific organ donation and transplantation system, organ transplants exceeded 48,000 in 2024, representing a 3.3% increase from those performed in 2023. Therefore, the rising prevalence of organ failures is driving the growth of the artificial vital organs and medical bionics market.
The rise in the elderly population is expected to drive the growth of the artificial vital organs and medical bionics market going forward. The elderly population consists of individuals aged 60 or 65 and above who require customized care and services due to aging-related health and lifestyle challenges. The elderly population is increasing due to longer life expectancy supported by improved healthcare systems and better living standards. Artificial vital organs and medical bionics support the elderly population by replacing or enhancing declining biological functions, thereby improving mobility, independence, and overall quality of life. For example, in January 2024, according to a report published by Population Reference Bureau, a US-based non-profit organization responsible for collecting statistical data for research and academic use, the number of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, reflecting a 47% increase. As a result, this age group’s share of the total US population will rise from 17% to 23% during this timeframe. Therefore, the increase in the elderly population is driving the growth of the artificial vital organs and medical bionics market.
Major companies operating in the artificial vital organs and medical bionics market are developing advanced products, such as bionic pancreas systems, to improve patient outcomes and meet the increasing demand for innovative medical solutions. A bionic pancreas is a sophisticated medical device designed to automate blood glucose regulation in individuals with diabetes by replicating the functions of a healthy pancreas. For example, in December 2023, Beta Bionics Inc., a US-based medical technology company, launched the iLet Bionic Pancreas, an autonomous insulin delivery system that simplifies diabetes management by automatically adjusting insulin delivery based on the user’s weight. This approach removes the need for healthcare providers to configure complex settings such as insulin-to-carbohydrate ratios, correction factors, or preset basal rates, thereby reducing the burden on both patients and clinicians.
Major companies operating in the artificial vital organs and medical bionics market are Abiomed Inc., Abbott Laboratories, Medtronic Plc, Fresenius Medical Care AG, Asahi Kasei Corporation, Boston Scientific Corporation, Biomet Inc., Terumo Corporation, Edwards Lifesciences Corporation, Otto Bock Healthcare GmbH, Nikkiso Co. Ltd., Cochlear Ltd., Ossur, Cirtec Medical, Heartware International Inc., Berlin Heart GmbH, SynCardia Systems LLC, Ekso Bionics Holdings Inc., Jarvik Heart Inc., CARMAT, Iwalk Inc., BiVACOR Inc., Nano Retina Inc., Second Sight Medical Products Inc., St. Jude Medical Inc.
North America was the largest region in the artificial vital organs and medical bionics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial vital organs and medical bionics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial vital organs and medical bionics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the artificial vital organs and medical bionics market by increasing the cost of imported components, such as electronic sensors, mechanical pumps, and specialized biomaterials. Segments like electronic medical bionics and artificial heart devices are particularly impacted, with Asia-Pacific regions including China and India facing higher import duties. This has raised production and procurement costs while causing temporary supply chain disruptions. Positively, tariffs have encouraged local manufacturing, innovation in material sourcing, and investment in domestic production capacities to reduce dependency on imports.
The artificial vital organs and medical bionics market research report is one of a series of new reports that provides artificial vital organs and medical bionics market statistics, including artificial vital organs and medical bionics industry global market size, regional shares, competitors with a artificial vital organs and medical bionics market share, detailed artificial vital organs and medical bionics market segments, market trends and opportunities, and any further data you may need to thrive in the artificial vital organs and medical bionics industry. This artificial vital organs and medical bionics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Artificial vital organs are engineered devices that replicate the function of essential organs, while medical bionics integrates biological and electronic systems to restore or enhance bodily functions. The primary aim is to sustain life, improve quality of life in cases of severe organ failure, and help recover or enhance lost physical abilities.
The key artificial vital organs and medical bionics consist of artificial vital organs and medical bionics. Artificial vital organs are technologically developed devices that mimic the functions of natural organs such as the heart, lungs, or kidneys to support life in patients experiencing organ failure. These systems may be mechanical or electronic in nature and are commonly used by hospitals, clinics, and other healthcare providers.
The artificial vital organs and medical bionics market consists of sales of artificial hearts, artificial kidneys, artificial lungs, artificial pancreas, bionic limbs, cochlear implants, retinal implants, neuroprosthetics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The artificial vital organs and medical bionics market size is expected to see strong growth in the next few years. It will grow to $70.67 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to advancements in electronic and smart bionic devices, rising investment in r&d for artificial organs, increasing adoption of minimally invasive implantation procedures, growth in personalized medicine and patient-specific solutions, expansion of hospitals and clinics offering bionic therapies. Major trends in the forecast period include rising adoption of artificial heart and kidney devices, increasing integration of neural implants and bionic organs, growth in rehabilitation and assistive technologies, emphasis on customizable and patient-specific solutions, expansion of clinical trials and research applications.
The rising prevalence of organ failures is expected to propel the growth of the artificial vital organs and medical bionics market going forward. Organ failure is a serious condition in which one or more organs lose their ability to perform essential functions, resulting in severe health complications and potentially life-threatening outcomes. The increase in organ failures is driven by higher rates of chronic conditions such as diabetes, hypertension, and heart disease, as well as inherited conditions and genetic predispositions that contribute to organ failure. Artificial vital organs and medical bionics help manage organ failure by providing life-sustaining support and restoring critical functions in patients with damaged organs. For instance, in January 2025, according to the Organ Procurement and Transplantation Network, a US-based non-profit scientific organ donation and transplantation system, organ transplants exceeded 48,000 in 2024, representing a 3.3% increase from those performed in 2023. Therefore, the rising prevalence of organ failures is driving the growth of the artificial vital organs and medical bionics market.
The rise in the elderly population is expected to drive the growth of the artificial vital organs and medical bionics market going forward. The elderly population consists of individuals aged 60 or 65 and above who require customized care and services due to aging-related health and lifestyle challenges. The elderly population is increasing due to longer life expectancy supported by improved healthcare systems and better living standards. Artificial vital organs and medical bionics support the elderly population by replacing or enhancing declining biological functions, thereby improving mobility, independence, and overall quality of life. For example, in January 2024, according to a report published by Population Reference Bureau, a US-based non-profit organization responsible for collecting statistical data for research and academic use, the number of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, reflecting a 47% increase. As a result, this age group’s share of the total US population will rise from 17% to 23% during this timeframe. Therefore, the increase in the elderly population is driving the growth of the artificial vital organs and medical bionics market.
Major companies operating in the artificial vital organs and medical bionics market are developing advanced products, such as bionic pancreas systems, to improve patient outcomes and meet the increasing demand for innovative medical solutions. A bionic pancreas is a sophisticated medical device designed to automate blood glucose regulation in individuals with diabetes by replicating the functions of a healthy pancreas. For example, in December 2023, Beta Bionics Inc., a US-based medical technology company, launched the iLet Bionic Pancreas, an autonomous insulin delivery system that simplifies diabetes management by automatically adjusting insulin delivery based on the user’s weight. This approach removes the need for healthcare providers to configure complex settings such as insulin-to-carbohydrate ratios, correction factors, or preset basal rates, thereby reducing the burden on both patients and clinicians.
Major companies operating in the artificial vital organs and medical bionics market are Abiomed Inc., Abbott Laboratories, Medtronic Plc, Fresenius Medical Care AG, Asahi Kasei Corporation, Boston Scientific Corporation, Biomet Inc., Terumo Corporation, Edwards Lifesciences Corporation, Otto Bock Healthcare GmbH, Nikkiso Co. Ltd., Cochlear Ltd., Ossur, Cirtec Medical, Heartware International Inc., Berlin Heart GmbH, SynCardia Systems LLC, Ekso Bionics Holdings Inc., Jarvik Heart Inc., CARMAT, Iwalk Inc., BiVACOR Inc., Nano Retina Inc., Second Sight Medical Products Inc., St. Jude Medical Inc.
North America was the largest region in the artificial vital organs and medical bionics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial vital organs and medical bionics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial vital organs and medical bionics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the artificial vital organs and medical bionics market by increasing the cost of imported components, such as electronic sensors, mechanical pumps, and specialized biomaterials. Segments like electronic medical bionics and artificial heart devices are particularly impacted, with Asia-Pacific regions including China and India facing higher import duties. This has raised production and procurement costs while causing temporary supply chain disruptions. Positively, tariffs have encouraged local manufacturing, innovation in material sourcing, and investment in domestic production capacities to reduce dependency on imports.
The artificial vital organs and medical bionics market research report is one of a series of new reports that provides artificial vital organs and medical bionics market statistics, including artificial vital organs and medical bionics industry global market size, regional shares, competitors with a artificial vital organs and medical bionics market share, detailed artificial vital organs and medical bionics market segments, market trends and opportunities, and any further data you may need to thrive in the artificial vital organs and medical bionics industry. This artificial vital organs and medical bionics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Artificial vital organs are engineered devices that replicate the function of essential organs, while medical bionics integrates biological and electronic systems to restore or enhance bodily functions. The primary aim is to sustain life, improve quality of life in cases of severe organ failure, and help recover or enhance lost physical abilities.
The key artificial vital organs and medical bionics consist of artificial vital organs and medical bionics. Artificial vital organs are technologically developed devices that mimic the functions of natural organs such as the heart, lungs, or kidneys to support life in patients experiencing organ failure. These systems may be mechanical or electronic in nature and are commonly used by hospitals, clinics, and other healthcare providers.
The artificial vital organs and medical bionics market consists of sales of artificial hearts, artificial kidneys, artificial lungs, artificial pancreas, bionic limbs, cochlear implants, retinal implants, neuroprosthetics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Artificial Vital Organs and Medical Bionics Market Characteristics
3. Artificial Vital Organs and Medical Bionics Market Supply Chain Analysis
4. Global Artificial Vital Organs and Medical Bionics Market Trends and Strategies
5. Artificial Vital Organs and Medical Bionics Market Analysis of End Use Industries
7. Global Artificial Vital Organs and Medical Bionics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Artificial Vital Organs and Medical Bionics Total Addressable Market (TAM) Analysis for the Market
9. Artificial Vital Organs and Medical Bionics Market Segmentation
10. Artificial Vital Organs and Medical Bionics Market Regional and Country Analysis
11. Asia-Pacific Artificial Vital Organs and Medical Bionics Market
12. China Artificial Vital Organs and Medical Bionics Market
13. India Artificial Vital Organs and Medical Bionics Market
14. Japan Artificial Vital Organs and Medical Bionics Market
15. Australia Artificial Vital Organs and Medical Bionics Market
16. Indonesia Artificial Vital Organs and Medical Bionics Market
17. South Korea Artificial Vital Organs and Medical Bionics Market
18. Taiwan Artificial Vital Organs and Medical Bionics Market
19. South East Asia Artificial Vital Organs and Medical Bionics Market
20. Western Europe Artificial Vital Organs and Medical Bionics Market
21. UK Artificial Vital Organs and Medical Bionics Market
22. Germany Artificial Vital Organs and Medical Bionics Market
23. France Artificial Vital Organs and Medical Bionics Market
24. Italy Artificial Vital Organs and Medical Bionics Market
25. Spain Artificial Vital Organs and Medical Bionics Market
26. Eastern Europe Artificial Vital Organs and Medical Bionics Market
27. Russia Artificial Vital Organs and Medical Bionics Market
28. North America Artificial Vital Organs and Medical Bionics Market
29. USA Artificial Vital Organs and Medical Bionics Market
30. Canada Artificial Vital Organs and Medical Bionics Market
31. South America Artificial Vital Organs and Medical Bionics Market
32. Brazil Artificial Vital Organs and Medical Bionics Market
33. Middle East Artificial Vital Organs and Medical Bionics Market
34. Africa Artificial Vital Organs and Medical Bionics Market
36. Artificial Vital Organs and Medical Bionics Market Competitive Landscape and Company Profiles
37. Artificial Vital Organs and Medical Bionics Market Other Major and Innovative Companies
40. Artificial Vital Organs and Medical Bionics Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Artificial Vital Organs And Medical Bionics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses artificial vital organs and medical bionics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for artificial vital organs and medical bionics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The artificial vital organs and medical bionics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Artificial Vital Organs; Medical Bionics2) By Technology: Mechanical; Electronic
3) By Application: Hospitals; Clinics; Other Applications
Subsegments:
1) By Artificial Vital Organs: Artificial Heart; Artificial Kidney; Artificial Liver; Artificial Lungs; Artificial Pancreas2) By Medical Bionics: Bionic Limbs; Bionic Eyes; Bionic Ears; Neural Implants; Bionic Organs
Companies Mentioned: Abiomed Inc.; Abbott Laboratories; Medtronic Plc; Fresenius Medical Care AG; Asahi Kasei Corporation; Boston Scientific Corporation; Biomet Inc.; Terumo Corporation; Edwards Lifesciences Corporation; Otto Bock Healthcare GmbH; Nikkiso Co. Ltd.; Cochlear Ltd.; Ossur; Cirtec Medical; Heartware International Inc.; Berlin Heart GmbH; SynCardia Systems LLC; Ekso Bionics Holdings Inc.; Jarvik Heart Inc.; CARMAT; Iwalk Inc.; BiVACOR Inc.; Nano Retina Inc.; Second Sight Medical Products Inc.; St. Jude Medical Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Artificial Vital Organs and Medical Bionics market report include:- Abiomed Inc.
- Abbott Laboratories
- Medtronic Plc
- Fresenius Medical Care AG
- Asahi Kasei Corporation
- Boston Scientific Corporation
- Biomet Inc.
- Terumo Corporation
- Edwards Lifesciences Corporation
- Otto Bock Healthcare GmbH
- Nikkiso Co. Ltd.
- Cochlear Ltd.
- Ossur
- Cirtec Medical
- Heartware International Inc.
- Berlin Heart GmbH
- SynCardia Systems LLC
- Ekso Bionics Holdings Inc.
- Jarvik Heart Inc.
- CARMAT
- Iwalk Inc.
- BiVACOR Inc.
- Nano Retina Inc.
- Second Sight Medical Products Inc.
- St. Jude Medical Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 51.07 Billion |
| Forecasted Market Value ( USD | $ 70.67 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
